LAE104

LAE104 is a preclinical-stage drug candidate being developed by Laekna Therapeutics for the treatment of liver fibrosis. It is part of a proprietary platform focused on the depletion of activated hepatic stellate cells (aHSCs), which are the primary cells responsible for the secretion of extracellular matrix proteins and the subsequent formation of scar tissue in the liver. By specifically targeting and eliminating these activated cells, LAE104 aims to halt the progression of fibrosis and potentially promote the regression of existing liver damage. While confirmed as a key asset in Laekna's fibrosis pipeline, specific details regarding its molecular modality and precise binding targets have not yet been publicly disclosed.